OCULAR THERAPEUTIX, INC — fact timeline

OCULAR THERAPEUTIX, INC reported financial results for first quarter ended March 31, 2026.

“On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026.”

OCULAR THERAPEUTIX, INC: Amended restated certificate of incorporation to provide for officer exculpation (effective 2025-06-11).

“At the 2025 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to update its existing director exculpation provision to include the exculpation of certain of the Company’s senior corporate officers, subject to specified limitations. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 11, 2025.”

Donald Notman was appointed as Chief Operating Officer at OCULAR THERAPEUTIX, INC.

“On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Donald Notman to serve as Chief Operating Officer of the Company.”

OCULAR THERAPEUTIX, INC reported first quarter ended March 31, 2024 results: revenue $14.8 million, net income $(64.8) million, EPS $(0.49) per share.

“Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028. Total net revenue was $14.8 million for the first quarter of 2024, a 10.4% increase over total net revenue of $13.4 million in the comparable period in 2023, driven by increased DEXTENZA sales. Total net revenue”

Rabia Gurses Ozden, M.D. departed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.

“Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.”

Nadia Waheed, M.D. was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.

“On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.”

Antony C. Mattessich resigned as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.

“On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.”

Pravin U. Dugel, M.D. was appointed as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.

“On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.”

OCULAR THERAPEUTIX, INC reported the full year ended December 31, 2023 results: revenue $58.4 million.

“Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%.”

OCULAR THERAPEUTIX, INC reported the fourth quarter 2023 results: revenue $14.8 million, net income $(29.2) million, EPS $(0.35) per share on both a basic and diluted basis.

“Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales. Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%. Research and development expenses for the fourth quarter of 2023 were $16.2 million versus $13.5 million for the comparable period in 2022, driven primarily by an increase in overall clinical and regulatory expenses associated with product development programs. Overall R&D expenses for the full year increased $7.6 million to $61.1 million from $53.5 million in 2022, reflecting the timing and conduct of our clinical trials. Selling and marketing expenses were $9.2 million in the fourth quarter of 2023, as compared to $10.5 million for the comparable quarter of 2022, primarily reflecting a reduction in personnel costs driven by lower expense for stock-based compensation and other items. Overall, se”

OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2023 results: revenue approximately $57.9 million.

“its preliminary, unaudited cash and cash equivalents were approximately $195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023, was approximately $57.9 million.”

OCULAR THERAPEUTIX, INC entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $325.0 million (effective 2024-02-21).

“On February 21, 2024, Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase 10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant (the “Private Placement”).”

Pravin U. Dugel, M.D. was appointed as Executive Chairman at OCULAR THERAPEUTIX, INC.

“On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024”